| |
MJS
|
MJ
|
MS
|
JS
|
M
|
J
|
S
|
Overall
|
|---|
|
Variants assesseda
|
181
|
13
|
37
|
28
|
31
|
26
|
48
|
364
|
|
True positives
b
(% true positive)
|
179 (98.9%)
|
5 (38.5%)
|
29 (78.4%)
|
10 (35.7%)
|
4 (12.9%)
|
1 (3.8%)
|
1 (2.1%)
|
229 (62.9%)
|
|
Germlinec
|
1
|
0
|
5
|
3
|
15
|
4
|
11
|
39
|
|
Did not validatec
|
1
|
8
|
3
|
15
|
12
|
21
|
36
|
97
|
- Abbreviations: J, JointSNVMix2; JS, JointSNVMix2 + SomaticSniper; M, MuTect, MJ, MuTect + JointSNVMix2; MJS, MuTect + JointSNVMix2; + SomaticSniper; MS, MuTect + SomaticSniper; NRAF, non-reference allele frequency; S, SomaticSniper; SNV, single nucleotide variant.
- aNumber of sites that were successfully amplified and Sanger sequenced.
- bIndicates the number of SNVs that were confirmed as somatic.
- cFalse-positive SNVs were either detected in the matched germline (normal) sample ('Germline’) or did not validate in the tumor sample ('Did not validate’).
